Stevanato Group S.p.A. (STVN)

Market Cap	5.65B
Revenue (ttm)	1.22B
Net Income (ttm)	127.92M
Shares Out	272.90M
EPS (ttm)	0.48
PE Ratio	43.28
Forward PE	35.77
Dividend	$0.06 (0.28%)
Ex-Dividend Date	Jun 4, 2024

Volume	33,124
Open	20.87
Previous Close	20.56
Day's Range	20.08 - 20.95
52-Week Range	16.56 - 34.73
Beta	0.59
Analysts	Buy
Price Target	27.50 (+32.88%)
Earnings Date	Nov 5, 2024

About STVN

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines,...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 16, 2021
• Employees: 5,634
• Stock Exchange: NYSE
• Ticker Symbol: STVN
• Website: https://www.stevanatogroup.com

Financial Performance

In 2023, Stevanato Group's revenue was 1.09 billion, an increase of 10.34% compared to the previous year's 983.68 million. Earnings were 145.63 million, an increase of 1.95%.

Financial numbers in EUR

Analyst Forecast

According to 6 analysts, the average rating for STVN stock is "Buy." The 12-month stock price forecast is $27.5, which is an increase of 32.88% from the latest price.

Price Target

$27.5

(32.88% upside)

Analyst Consensus: Buy